FILTER
FILTERED INTERVIEW RESULTS
Gerardo Berea Montes
SPECIAL GASES DIRECTOR, GRUPO INFRA
Grupo Infra speaks to GBR about opportunities in special gases in Mexico.
Miguel Valdivia
COMMERCIAL DIRECTOR, TRADE CHEMICALS & PRODUCTS
Trade Chemicals & Products explains how it has continued supplying its customers in Mexico with the chemical products that they need despite shortages and price increases.
Maggie Gómez-Rábago
DIRECTOR GENERAL, CHARLOTTE CHEMICAL
Charlotte Chemicals comments on the trends in Mexico’s chemical supply market.
Roger Marchioni
ASIA DIRECTOR, CHEMICALS AND POLYMERS, BRASKEM
Braskem describes its expansion in Asia.
Francisco Rubio
PRESIDENT, KEMIKALS
"Now innovation is no longer just about products but about logistics and business relationships. The industry is reinventing itself."
Santiago Carús
MANAGING DIRECTOR, EUROMEX LOGISTICS
Euromex Logistics explains how it is coping with demand in Mexico.
Muthukumar Paramasivam
BUSINESS HEAD, AROMATICS & PET – AMERICAS, INDORAMA VENTURES
Indorama Ventures is the world’s largest PET resin producer.
Danny Foong
GENERAL MANAGER, ARKEMA SOUTHEAST ASIA
Arkema updates GBR on its investments in Singapore.
Law Gee Yong
DIRECTOR OF POLICY & PLANNING DEPARTMENT, ENERGY MARKET AUTHORITY
The Energy Market Authority’s (EMA) main goals are to ensure a reliable and secure energy supply, promote effective competition in the energy market and develop a dynamic energy sector in Singapore.
Andrew Taylor
PRESIDENT, GROWTH MARKETS, (ASIA, MIDDLE EAST, AFRICA, AND LATIN AMERICA) TATE & LYLE
Tate & Lyle is now transformed into a purpose-led, growth-focused global food and beverage solutions business, serving faster growing specialty markets.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
